Vaxart Earnings Call Transcripts
Fiscal Year 2026
-
Management highlighted progress on clinical milestones, cost-saving initiatives, and global partnership efforts. The oral vaccine platform is positioned to address vaccine fatigue and global immunization needs, with key data readouts expected in 2026 and a cash runway into Q2 2027.
-
The oral pill vaccine platform offers both systemic and mucosal immunity, with ongoing phase IIb trials for COVID-19 and advanced programs in norovirus and influenza. Strategic partnerships, notably with Dynavax (now Sanofi), provide funding and validation, while upcoming data readouts and potential expansion into new indications are expected to drive growth.
-
Oral pill vaccines are being developed to improve convenience, access, and immune response, with strong preclinical and clinical data supporting efficacy and safety. Key COVID-19 and norovirus trial results are expected in 2026, potentially marking major milestones.
Fiscal Year 2025
-
Revenue surged to $237.3M in 2025, driven by BARDA and Dynavax deals, with cash runway into Q2 2027. Key COVID-19 and norovirus vaccine trials are progressing, with major data readouts expected in 2026 and significant milestone payments possible.
-
Secured a transformative partnership with Dynavax for the oral COVID-19 vaccine, extending cash runway into Q2 2027 and validating the platform. Q3 revenue surged to $72.4 million, and robust progress was made in both COVID-19 and norovirus programs.
-
A thermally stable oral pill vaccine platform is advancing programs for norovirus, COVID-19, and flu, with significant clinical progress and upcoming milestones including a phase 2B norovirus study and a large COVID-19 trial. The platform aims to address unmet needs and provide alternatives to traditional vaccines.
-
Q2 2025 saw a major revenue increase from BARDA contracts, positive norovirus phase I data, and strong preclinical influenza results. COVID-19 trial enrollment halted at 5,000, with top-line data expected in 2026. Nasdaq relisting efforts continue amid cost controls and funding pursuits.
-
The meeting covered director elections, a failed reverse stock split proposal, and approval of the accounting firm. Management addressed shareholder questions on partnerships, capital strategy, and next steps after the reverse split vote.
-
Phase I results show the second-generation oral norovirus vaccine significantly boosts blocking antibody titers, especially at high dose, with a strong safety profile. The vaccine targets major genotypes and offers broad public health and market potential. A phase IIb study is planned for 2025.
-
The oral vaccine platform offers convenience, strong mucosal immunity, and economic benefits. The COVID-19 program is advancing with robust BARDA funding and a large phase 2b trial, while the norovirus program expects key data mid-year and is attracting partnership interest. The pipeline also includes promising influenza candidates.
-
Q1 2025 revenue surged to $20.9M, driven by BARDA contracts, with cash runway into Q1 2026. The COVID-19 phase 2B trial resumed after the stop work order was lifted, and norovirus phase 1 enrollment completed, with top-line data expected mid-2025.
-
A novel oral vaccine platform offers needle-free, thermostable immunization with strong mucosal and systemic responses. Norovirus and COVID-19 programs are advancing, with key clinical milestones expected in 2024–2025, and BARDA funding supporting COVID-19 development.
Fiscal Year 2024
-
Oral vaccine platform advanced with strong safety and immunogenicity data; 2024 revenue rose to $28.7M, and cash runway extends into Q4 2025 after cost reductions. COVID-19 trial paused by BARDA stop work order, while norovirus program progresses with phase I data expected mid-2025.
-
Q3 2024 revenue more than doubled year-over-year, driven by BARDA contracts, with a strong cash position and continued progress in COVID-19, norovirus, and HPV vaccine programs. COVID-19 phase II-B trial enrollment is on track, and new norovirus constructs show improved potency.
-
Q2 2024 revenue rose to $6.4M, driven by BARDA contract work, with over $127M in liquidity post-quarter. Major progress includes a $453M BARDA award for COVID-19, positive norovirus trial results, and a cash runway into 2026.